Salmon Evolution reports success in tackling AGD
Land based fish farmer Salmon Evolution says that the biological issues affecting its site in Indre Harøy, Norway have now been resolved.
In May the company said it was experiencing increased mortality levels following the discovery of biological problems which were mainly related to amoebic gill disease (AGD).
The company then embarked on a water treatment programme designed to normalise the situation.
Salmon Evolution said today, in an operational update, that it is now recording normal mortality levels across all fish groups.
The statement added: “As per 30 June 2023 the Company had around 1,047 tonnes (LW) of standing biomass, up 31% since 21 May 2023. Batch 6 and 7 were also stocked during the quarter and are expected to add further biomass growth momentum over the coming months.
“The Company expects to initiate next harvest late in Q3 2023 and further to reach steady state production volumes of 7,900 tonnes HOG p.a. during Q4 2023.
“We are very pleased with the strong biological performance seen over the last month and to be back in production modus.”
CEO Trond Håkon Schaug-Pettersen said: “During the second quarter we have gained invaluable operational know-how and look forward to continuing our production ramp-up and preparing for the next harvest.”
Salmon Evolution is company targeting a production capacity of 100,000 tonnes HOG by 2032 at its facility, which operates a hybrid flow-through system (HFS).
It has also entered into a joint venture with Dongwon Industries under which the parties will develop, construct and operate a land-based salmon farming facility in South Korea with an annual production capacity of 16,800 tonnes HOG, using Salmon Evolution’s chosen HFS technology.
